J&J details on job cuts
Executive Summary
Johnson & Johnson plans eliminate 900 U.S. sales positions at its Ortho McNeil Janssen Pharmaceuticals division. The cuts will come at the end of the second quarter of 2009 and affect both primary and specialty care sales forces. As multiple players - such as payers, patients and policymakers - gain influence on prescribing decisions, fewer sales reps detailing to physicians are needed, the company indicated. While prescribing physicians remain an important influence, the company has a dedicated team looking at other groups "to ensure that we understand what represents value to them and that we are providing it," the company says
You may also be interested in...
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.